Aldeyra Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 10
- Market Cap
- $319M
- Website
- http://www.aldeyra.com
- Introduction
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- Other: Standard surgical care procedureDrug: ADX-2191 (intravitreal methotrexate 0.8%)
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT04136366
- Locations
- 🇺🇸
Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Associated Retinal Consultants, Royal Oak, Michigan, United States
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
- Conditions
- Dry Eye
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BIDDrug: Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT03916042
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- Conditions
- Dry Eye
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%) QIDDrug: Vehicle Ophthalmic Solution QIDDrug: Vehicle Ophthalmic Solution QID to BIDDrug: Reproxalap Ophthalmic Solution (0.25%) QID to BID
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03879863
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
- Conditions
- Conjunctivitis, Allergic
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Reproxalap Ophthalmic Solution (0.5%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03709121
- Locations
- 🇨🇦
Inflamax Research Limited, Mississauga, Ontario, Canada
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.5%)Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03660878
- Locations
- 🇺🇸
Slade & Baker Vision, Houston, Texas, United States
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic SolutionDrug: Reproxalap Ophthalmic Solution (0.5%)
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT03494504
- Locations
- 🇺🇸
Eye Clinics of South Texas, San Antonio, Texas, United States
🇺🇸R & R Research, LLC, San Antonio, Texas, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
- Conditions
- Sjogren-Larsson Syndrome
- Interventions
- Drug: ADX-102 1% Topical Dermal Cream (reproxalap)Drug: Vehicle of ADX-102 Topical Dermal Cream
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03445650
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic SolutionDrug: Reproxalap Ophthalmic Solution (0.1%)
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03404115
- Locations
- 🇺🇸
Midwest Cornea Associates, Indianapolis, Indiana, United States
🇺🇸Total Eye Care, Memphis, Tennessee, United States
🇺🇸Central Maine Eye Care, Lewiston, Maine, United States
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: ADX-102 Ophthalmic Solution (0.5%)Drug: ADX-102 Ophthalmic Solution (0.1%)Drug: ADX-102 Ophthalmic Lipid Solution (0.5%)
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03162783
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- Drug: ADX-102 Ophthalmic Solution (0.5%)Drug: Vehicle of ADX-102 Ophthalmic Solution
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT03131154
- Locations
- 🇺🇸
Walman Eye Center, Sun City, Arizona, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Levenson Eye Associates, Jacksonville, Florida, United States